Product Name: Nek7 (191-198) pT191+pS195
Product Number: PE-04AHR99
Size: 200 µg      Price:65.00
1 mg      $US129.00
Peptide Name: Nek7 (191-198) pT191+pS195

Product Use: Services as a blocking peptide for use with the Nek7-pT191+S195 rabbit polyclonal antibody (Cat. No.: AB-PK735) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T191 and S195 phosphorylation is predicted to be stimulatory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: pT-AAH-pS-LVG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1088.02 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Nek7 - pT191+pS195 phosphosite-specific antibody (Cat. No.: AB-PK735)

Scientific Background: Nek7 is a protein-serine/threonine kinase that is a member of the Other group of protein kinases in the Nek family. This kinase is highly expressed and widely distributed in most tested human tissues. Nek7 is a member of the NIMA family of serine/threonine kinases. In contrast to the other documented NimA-related kinases, Nek7 harbor its catalytic domain in the C-terminus of the protein. Immunofluorescence studies indicate that Nek7 is cytoplasmic and located on chromosome 1. The major protein kinase that is active on the p70 S6 kinase hydrophobic regulatory site (FXXFS/TF/Y) T412, was purified from rat liver and identified as Nek7. Nek7 phosphotransferase activity is rapidly and efficiently increased by serum deprivation, and may be regulated in a cell cycle-dependent manner. Nek7 has been linked with the development of ovarian serous carcinomas. Nek7 has been significantly associated with certain clinicopathologic indices in gallbladder carcinomas. The high level expression of Nek7, FoxM1 and Plk1 was significantly associated with shorter overall survival time in 76 specimens of gallbladder carcinomas, pericarcinomas and normal tissues (PubMEd: 23359173).